Injection Pen Market Size to grow by USD 25.51 billion between 2024-2028
According to a research report “ Injection Pen Market” by Product (Growth hormone, Diabetes, Fertility, Osteoporosis, Others) Type (Disposable injection pen, Reusable injection pen) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 25.51 billion, at a CAGR of 8.13% during the forecast period. The injection pen market is poised for significant growth due to the increasing prevalence of chronic conditions, such as diabetes, multiple sclerosis (MS), cancer, and cardiovascular diseases. Injection pens are a preferred mode of medication delivery for patients managing these conditions, particularly those with diabetes who require regular insulin injections. The World Health Organization estimates that non-communicable diseases, including cancer and cardiovascular diseases, accounted for 71% of global deaths in 2016. With the incidence of these diseases on the rise, the demand for injection pens is anticipated to surge, driving market expansion throughout the forecast period.
Browse market data tables, figures, and in-depth TOC on “Injection Pen Market” by Product (Growth hormone, Diabetes, Fertility, Osteoporosis, Others) Type (Disposable injection pen, Reusable injection pen) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By Product, the Growth hormone segment is projected to dominate the market size in 2024
In the Injection Pen Market, disposable pens held the largest market share in 2023. This segment's dominance is anticipated to persist throughout the forecast period. Disposable injection pens offer several advantages over reusable pens. They come with prefilled insulin cartridges, ensuring ease of use and eliminating the need for repeated insulin loading. The risk of dosage tampering, which can occur during refilling of reusable pens, is avoided with disposable pens. Furthermore, disposable pens cater to the requirement of administering small insulin doses, which is crucial for certain patient populations, such as children with type-1 diabetes. Despite their advantages, current disposable injection pens are limited to delivering 1-unit doses only.
By Type, Disposable injection pen segment is expected to hold the largest market size for the year 2024
Human growth hormone (hGH) deficiency impairs the body's natural growth process, leading to a decrease in growth rate. This condition affects both pediatric and adult populations, with most cases identified in the early years (age 2-3). hGH deficiency can be congenital or acquired due to various medical conditions or injuries. To effectively manage this condition, patients require regular hGH injections. The increasing prevalence of hGH deficiency is anticipated to boost the demand for injection pen devices, offering convenience, accuracy, and ease of use for patients undergoing long-term treatment.
North America is forecasted to hold the largest market size by region in 2024
The North American injection pen market is projected to expand at a steady pace, fueled by the substantial revenue generation from key contributors, the United States and Canada. Major industry players headquartered in this region, particularly in high-growth markets such as the US and Canada, are instrumental in driving market expansion. Diabetic pens have witnessed significant traction in the region due to their numerous benefits. The presence of these key players and the popularity of diabetic pens are crucial factors propelling the growth of the injection pen market in North America.
The Injection Pen Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
The injection pen market is witnessing significant growth due to the rising prevalence of chronic diseases such as Diabetes, Cancer, Multiple Sclerosis, Cardiovascular disease (CVD), and Osteoporosis. Insulin injection pens, in particular, have gained popularity as a convenient alternative to traditional syringes and vials. These devices use drug cartridges, eliminating the need for syringes, needles, and plungers. CVS Caremark and other pharmacy benefit managers are driving the market's growth by partnering with manufacturers to offer insulin pen options to patients. Governments and insurance companies are also promoting the use of injector pens to improve patient compliance and reduce needle-stick injuries and needle anxiety. Technological advancements, such as needle-free devices and biosimilars, are further fueling market growth. However, challenges remain in emerging markets due to poor reimbursement scenarios and regulatory approvals. Despite these hurdles, the market is expected to continue expanding as governments and insurance companies seek cost-effective solutions for managing chronic diseases.
Market Research Overview
The injection pen market is experiencing rapid adoption due to the increasing prevalence of chronic diseases such as diabetes, cardiovascular illnesses, stroke, blindness, kidney failure, and cancer, particularly in the elderly population. According to the World Health Organization, diabetes affects over 463 million people worldwide, and this number is projected to increase to 700 million by 2045. The convenience, simplicity of use, affordability, and precision of insulin pens have made them a preferred choice for diabetic patients, leading to a significant market growth. The market is segmented into disposable and reusable injection pens, with disposable pens holding the majority share due to their affordability and ease of use. Pharmacies and hospitals are the major distribution channels, with governments and insurance companies also playing a crucial role in driving market growth through initiatives and reimbursement policies. Technological advancements, such as automated injection pens with Bluetooth technology, are enhancing the user experience and improving treatment adherence. Companies like Medtronic Plc, with their InPen, are leading the way in this space. However, the market faces challenges such as poor reimbursement scenarios in developing regions, needle anxiety, and needle-stick injuries. The market is expected to grow at a CAGR of over 10% during the forecast period, with emerging economies and developing countries presenting significant opportunities. The market is also witnessing the entry of biosimilars and needle-free devices, adding to the competition. Overall, the injection pen market is poised for significant growth, driven by consumer knowledge, disposable income, and the increasing burden of chronic diseases.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
